  6 ADVERSE REACTIONS

  The following adverse reactions are discussed in more detail in other sections of the labeling.

 *     Hypersensitivity≠B-OSE_Labeled_AE  [see  Contraindications (4)  ] 
 *     Myelosuppression≠B-OSE_Labeled_AE ,  Immunosuppression≠B-OSE_Labeled_AE ,  Bone≠B-OSE_Labeled_AE   Marrow≠I-OSE_Labeled_AE   Failure≠I-OSE_Labeled_AE , and  Infections≠B-OSE_Labeled_AE  [see  Warnings and Precautions (5.1)  ] 
 *     Urinary≠B-OSE_Labeled_AE   Tract≠I-OSE_Labeled_AE  and Renal  Toxicity≠I-OSE_Labeled_AE  [see  Warnings and Precautions (5.2)  ] 
 *     Cardiotoxicity≠B-OSE_Labeled_AE  [see  Warnings and Precautions (5.3)  ] 
 *     Pulmonary≠B-OSE_Labeled_AE   Toxicity≠I-OSE_Labeled_AE  [see  Warnings and Precautions (5.4)  ] 
 *     Secondary≠B-OSE_Labeled_AE   Malignancies≠I-OSE_Labeled_AE  [see  Warnings and Precautions (5.5)  ] 
 *     Veno≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  occlusive≠I-OSE_Labeled_AE   Liver≠I-OSE_Labeled_AE   Disease≠I-OSE_Labeled_AE  [see  Warnings and Precautions (5.6)  ] 
 *     Embryo≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  Fetal≠I-OSE_Labeled_AE   Toxicity≠I-OSE_Labeled_AE  [see  Warnings and Precautions (5.7)  ] 
 *     Reproductive≠B-OSE_Labeled_AE   System≠I-OSE_Labeled_AE   Toxicity≠I-OSE_Labeled_AE  [see  Warnings and Precautions (5.8)  and  Use in Specific Populations (8.4  and  8.6)  ] 
 *     Impaired≠B-OSE_Labeled_AE   Wound≠I-OSE_Labeled_AE   Healing≠I-OSE_Labeled_AE  [see  Warnings and Precautions (5.9)  ] 
 *     Hyponatremia≠B-OSE_Labeled_AE  [see  Warnings and Precautions (5.10)  ] 
      EXCERPT:   Adverse reactions reported most often include neutropenia, febrile neutropenia, fever, alopecia, nausea, vomiting, and diarrhea. (  6.1  )
 

 To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare at 1-866-888-2472 or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch    .

 

  6.1 Common Adverse Reactions

    Hematopoietic system:  

  Neutropenia≠B-OSE_Labeled_AE  occurs in patients treated with cyclophosphamide. The degree of  neutropenia≠B-NonOSE_AE  is particularly important because it correlates with a  reduction≠B-NonOSE_AE   in≠I-NonOSE_AE   resistance≠I-NonOSE_AE   to≠I-NonOSE_AE   infections≠I-NonOSE_AE .  Fever≠B-NonOSE_AE  without documented  infection≠B-NonOSE_AE  has been reported in  neutropenic≠B-NonOSE_AE  patients.

   Gastrointestinal system:  

  Nausea≠B-OSE_Labeled_AE  and  vomiting≠B-OSE_Labeled_AE  occur with cyclophosphamide therapy.  Anorexia≠B-OSE_Labeled_AE  and, less frequently,  abdominal≠B-OSE_Labeled_AE   discomfort≠I-OSE_Labeled_AE  or pain and  diarrhea≠B-OSE_Labeled_AE  may occur. There are isolated reports of  hemorrhagic≠B-OSE_Labeled_AE   colitis≠I-OSE_Labeled_AE ,  oral≠B-OSE_Labeled_AE   mucosal≠I-OSE_Labeled_AE   ulceration≠I-OSE_Labeled_AE  and  jaundice≠B-OSE_Labeled_AE  occurring during therapy.

   Skin and its structures:  

  Alopecia≠B-OSE_Labeled_AE  occurs in patients treated with cyclophosphamide.  Skin≠B-OSE_Labeled_AE   rash≠I-OSE_Labeled_AE  occurs occasionally in patients receiving the drug.  Pigmentation≠B-OSE_Labeled_AE   of≠I-OSE_Labeled_AE   the≠I-OSE_Labeled_AE   skin≠I-OSE_Labeled_AE  and changes in nails can occur.

   6.2 Postmarketing Experience

  The following adverse reactions have been identified from clinical trials or post-marketing surveillance. Because they are reported from a population from unknown size, precise estimates of frequency cannot be made.

    Cardiac≠B-NonOSE_AE :   cardiac≠B-OSE_Labeled_AE   arrest≠I-OSE_Labeled_AE ,  ventricular≠B-OSE_Labeled_AE   fibrillation≠I-OSE_Labeled_AE ,  ventricular≠B-OSE_Labeled_AE   tachycardia≠I-OSE_Labeled_AE ,  cardiogenic≠B-OSE_Labeled_AE   shock≠I-OSE_Labeled_AE ,  pericardial≠B-OSE_Labeled_AE   effusion≠I-OSE_Labeled_AE  (progressing to  cardiac≠B-OSE_Labeled_AE   tamponade≠I-OSE_Labeled_AE ),  myocardial≠B-OSE_Labeled_AE   hemorrhage≠I-OSE_Labeled_AE ,  myocardial≠B-OSE_Labeled_AE   infarction≠I-OSE_Labeled_AE ,  cardiac≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE  (including  fatal≠B-NonOSE_AE  outcomes),  cardiomyopathy≠B-OSE_Labeled_AE ,  myocarditis≠B-OSE_Labeled_AE ,  pericarditis≠B-OSE_Labeled_AE ,  carditis≠B-OSE_Labeled_AE ,  atrial≠B-OSE_Labeled_AE   fibrillation≠I-OSE_Labeled_AE ,  supraventricular≠B-OSE_Labeled_AE   arrhythmia≠I-OSE_Labeled_AE ,  ventricular≠B-OSE_Labeled_AE   arrhythmia≠I-OSE_Labeled_AE ,  bradycardia≠B-OSE_Labeled_AE ,  tachycardia≠B-OSE_Labeled_AE ,  palpitations≠B-OSE_Labeled_AE ,  QT≠B-OSE_Labeled_AE   prolongation≠I-OSE_Labeled_AE .

    Congenital≠B-NonOSE_AE  ,≠I-NonOSE_AE   Familial≠I-NonOSE_AE   and≠I-NonOSE_AE   Genetic≠I-NonOSE_AE   :  intra≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  uterine≠I-OSE_Labeled_AE   death≠I-OSE_Labeled_AE ,  fetal≠B-OSE_Labeled_AE   malformation≠I-OSE_Labeled_AE ,  fetal≠B-OSE_Labeled_AE   growth≠I-OSE_Labeled_AE   retardation≠I-OSE_Labeled_AE ,  fetal≠B-OSE_Labeled_AE   toxicity≠I-OSE_Labeled_AE  (including  myelosuppression≠B-OSE_Labeled_AE ,  gastroenteritis≠B-OSE_Labeled_AE ).

    Ear≠B-NonOSE_AE   and≠I-NonOSE_AE   Labyrinth≠I-NonOSE_AE :   deafness≠B-OSE_Labeled_AE ,  hearing≠B-OSE_Labeled_AE   impaired≠I-OSE_Labeled_AE ,  tinnitus≠B-OSE_Labeled_AE .

    Endocrine≠B-NonOSE_AE :   water≠B-OSE_Labeled_AE   intoxication≠I-OSE_Labeled_AE .

    Eye≠B-NonOSE_AE :   visual≠B-OSE_Labeled_AE   impairment≠I-OSE_Labeled_AE ,  conjunctivitis≠B-OSE_Labeled_AE ,  lacrimation≠B-OSE_Labeled_AE .

    Gastrointestinal≠B-NonOSE_AE :   gastrointestinal≠B-OSE_Labeled_AE   hemorrhage≠I-OSE_Labeled_AE ,  acute≠B-OSE_Labeled_AE   pancreatitis≠I-OSE_Labeled_AE ,  colitis≠B-OSE_Labeled_AE ,  enteritis≠B-OSE_Labeled_AE ,  cecitis≠B-OSE_Labeled_AE ,  stomatitis≠B-OSE_Labeled_AE ,  constipation≠B-OSE_Labeled_AE ,  parotid≠B-OSE_Labeled_AE   gland≠I-OSE_Labeled_AE   inflammation≠I-OSE_Labeled_AE .

    General≠B-NonOSE_AE   Disorders≠I-NonOSE_AE   and≠I-NonOSE_AE   Administrative≠I-NonOSE_AE   Site≠I-NonOSE_AE   Conditions≠I-NonOSE_AE :   multiorgan≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE ,  general≠B-OSE_Labeled_AE   physical≠I-OSE_Labeled_AE   deterioration≠I-OSE_Labeled_AE ,  influenza≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  like≠I-OSE_Labeled_AE   illness≠I-OSE_Labeled_AE ,  injection≠B-OSE_Labeled_AE /infusion  site≠I-OSE_Labeled_AE   reactions≠I-OSE_Labeled_AE  (thrombosis, necrosis, phlebitis, inflammation, pain, swelling, erythema),  pyrexia≠B-OSE_Labeled_AE ,  edema≠B-OSE_Labeled_AE ,  chest≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  mucosal≠B-OSE_Labeled_AE   inflammation≠I-OSE_Labeled_AE ,  asthenia≠B-OSE_Labeled_AE ,  pain≠B-OSE_Labeled_AE ,  chills≠B-OSE_Labeled_AE ,  fatigue≠B-OSE_Labeled_AE ,  malaise≠B-OSE_Labeled_AE ,  headache≠B-OSE_Labeled_AE .

    Hematologic≠B-NonOSE_AE :   myelosuppression≠B-OSE_Labeled_AE ,  bone≠B-OSE_Labeled_AE   marrow≠I-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE ,  disseminated≠B-OSE_Labeled_AE   intravascular≠I-OSE_Labeled_AE   coagulation≠I-OSE_Labeled_AE  and  hemolytic≠B-OSE_Labeled_AE   uremic≠I-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE  (with  thrombotic≠B-OSE_Labeled_AE   microangiopathy≠I-OSE_Labeled_AE ).

    Hepatic≠B-NonOSE_AE :   veno≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  occlusive≠I-OSE_Labeled_AE   liver≠I-OSE_Labeled_AE   disease≠I-OSE_Labeled_AE ,  cholestatic≠B-OSE_Labeled_AE   hepatitis≠I-OSE_Labeled_AE ,  cytolytic≠B-OSE_Labeled_AE   hepatitis≠I-OSE_Labeled_AE ,  hepatitis≠B-OSE_Labeled_AE ,  cholestasis≠B-OSE_Labeled_AE ;  hepatotoxicity≠B-OSE_Labeled_AE  with  hepatic≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE ,  hepatic≠B-OSE_Labeled_AE   encephalopathy≠I-OSE_Labeled_AE ,  ascites≠B-OSE_Labeled_AE ,  hepatomegaly≠B-OSE_Labeled_AE ,  blood≠B-OSE_Labeled_AE   bilirubin≠I-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE ,  hepatic≠B-OSE_Labeled_AE   function≠I-OSE_Labeled_AE   abnormal≠I-OSE_Labeled_AE ,  hepatic≠B-OSE_Labeled_AE   enzymes≠I-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE .

    Immune≠B-NonOSE_AE :   immunosuppression≠B-OSE_Labeled_AE ,  anaphylactic≠B-OSE_Labeled_AE   shock≠I-OSE_Labeled_AE  and  hypersensitivity≠B-OSE_Labeled_AE   reaction≠I-OSE_Labeled_AE .

    Infections≠B-NonOSE_AE :  The following manifestations have been associated with  myelosuppression≠B-OSE_Labeled_AE  and  immunosuppression≠B-OSE_Labeled_AE  caused by cyclophosphamide: increased risk for and severity of  pneumonias≠B-NonOSE_AE  (including  fatal≠B-NonOSE_AE  outcomes), other  bacterial≠B-NonOSE_AE , fungal, viral, protozoal and, parasitic  infections≠I-NonOSE_AE ;  reactivation≠B-NonOSE_AE  of latent infections, (including  viral≠I-NonOSE_AE   hepatitis≠I-NonOSE_AE , tuberculosis),   Pneumocystis≠B-NonOSE_AE   jiroveci≠I-NonOSE_AE   ,  herpes≠B-NonOSE_AE   zoster≠I-NonOSE_AE ,   Strongyloides≠B-NonOSE_AE   ,  sepsis≠B-NonOSE_AE  and  septic≠B-NonOSE_AE   shock≠I-NonOSE_AE .

    Investigations≠B-NonOSE_AE :   blood≠B-OSE_Labeled_AE   lactate≠I-OSE_Labeled_AE   dehydrogenase≠I-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE ,  C≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  reactive≠I-OSE_Labeled_AE   protein≠I-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE .

    Metabolism≠B-NonOSE_AE   and≠I-NonOSE_AE   Nutrition≠I-NonOSE_AE :   hyponatremia≠B-OSE_Labeled_AE ,  fluid≠B-OSE_Labeled_AE   retention≠I-OSE_Labeled_AE ,  blood≠B-OSE_Labeled_AE   glucose≠I-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE ,  blood≠B-OSE_Labeled_AE   glucose≠I-OSE_Labeled_AE   decreased≠I-OSE_Labeled_AE .

    Musculoskeletal≠B-NonOSE_AE   and≠I-NonOSE_AE   Connective≠I-NonOSE_AE   Tissue≠I-NonOSE_AE   :  rhabdomyolysis≠B-OSE_Labeled_AE ,  scleroderma≠B-OSE_Labeled_AE ,  muscle≠B-OSE_Labeled_AE   spasms≠I-OSE_Labeled_AE ,  myalgia≠B-OSE_Labeled_AE ,  arthralgia≠B-OSE_Labeled_AE .

    Neoplasms≠B-NonOSE_AE :   acute≠B-OSE_Labeled_AE   leukemia≠I-OSE_Labeled_AE ,  myelodysplastic≠B-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE ,  lymphoma≠B-OSE_Labeled_AE ,  sarcomas≠B-OSE_Labeled_AE ,  renal≠B-OSE_Labeled_AE   cell≠I-OSE_Labeled_AE   carcinoma≠I-OSE_Labeled_AE ,  renal≠B-OSE_Labeled_AE   pelvis≠I-OSE_Labeled_AE   cancer≠I-OSE_Labeled_AE ,  bladder≠B-OSE_Labeled_AE   cancer≠I-OSE_Labeled_AE ,  ureteric≠B-OSE_Labeled_AE   cancer≠I-OSE_Labeled_AE ,  thyroid≠B-OSE_Labeled_AE   cancer≠I-OSE_Labeled_AE .

    Nervous≠B-NonOSE_AE   System≠I-NonOSE_AE :   encephalopathy≠B-OSE_Labeled_AE ,  convulsion≠B-OSE_Labeled_AE ,  dizziness≠B-OSE_Labeled_AE ,  neurotoxicity≠B-OSE_Labeled_AE  has been reported and manifested as  reversible≠B-OSE_Labeled_AE   posterior≠I-OSE_Labeled_AE   leukoencephalopathy≠I-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE ,  myelopathy≠B-OSE_Labeled_AE ,  peripheral≠B-OSE_Labeled_AE   neuropathy≠I-OSE_Labeled_AE ,  polyneuropathy≠B-OSE_Labeled_AE ,  neuralgia≠B-OSE_Labeled_AE ,  dysesthesia≠B-OSE_Labeled_AE ,  hypoesthesia≠B-OSE_Labeled_AE ,  paresthesia≠B-OSE_Labeled_AE ,  tremor≠B-OSE_Labeled_AE ,  dysgeusia≠B-OSE_Labeled_AE ,  hypogeusia≠B-OSE_Labeled_AE ,  parosmia≠B-OSE_Labeled_AE .

    Pregnancy≠B-NonOSE_AE :   premature≠B-OSE_Labeled_AE   labor≠I-OSE_Labeled_AE .

    Psychiatric≠B-NonOSE_AE :   confusional≠B-OSE_Labeled_AE   state≠I-OSE_Labeled_AE .

    Renal≠B-NonOSE_AE   and≠I-NonOSE_AE   Urinary≠I-NonOSE_AE :   renal≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE ,  renal≠B-OSE_Labeled_AE   tubular≠I-OSE_Labeled_AE   disorder≠I-OSE_Labeled_AE ,  renal≠B-OSE_Labeled_AE   impairment≠I-OSE_Labeled_AE ,  nephropathy≠B-OSE_Labeled_AE   toxic≠I-OSE_Labeled_AE ,  hemorrhagic≠B-OSE_Labeled_AE   cystitis≠I-OSE_Labeled_AE ,  bladder≠B-OSE_Labeled_AE   necrosis≠I-OSE_Labeled_AE ,  cystitis≠B-OSE_Labeled_AE   ulcerative≠I-OSE_Labeled_AE ,  bladder≠B-OSE_Labeled_AE   contracture≠I-OSE_Labeled_AE ,  hematuria≠B-OSE_Labeled_AE ,  nephrogenic≠B-OSE_Labeled_AE   diabetes≠I-OSE_Labeled_AE   insipidus≠I-OSE_Labeled_AE ,  atypical≠B-OSE_Labeled_AE   urinary≠I-OSE_Labeled_AE   bladder≠I-OSE_Labeled_AE   epithelial≠I-OSE_Labeled_AE   cells≠I-OSE_Labeled_AE .

    Reproductive≠B-NonOSE_AE   System≠I-NonOSE_AE :   infertility≠B-OSE_Labeled_AE ,  ovarian≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE ,  ovarian≠B-OSE_Labeled_AE   disorder≠I-OSE_Labeled_AE ,  amenorrhea≠B-OSE_Labeled_AE ,  oligomenorrhea≠B-OSE_Labeled_AE ,  testicular≠B-OSE_Labeled_AE   atrophy≠I-OSE_Labeled_AE ,  azoospermia≠B-OSE_Labeled_AE ,  oligospermia≠B-OSE_Labeled_AE .

    Respiratory≠B-NonOSE_AE :   pulmonary≠B-OSE_Labeled_AE   veno≠I-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  occlusive≠I-OSE_Labeled_AE   disease≠I-OSE_Labeled_AE ,  acute≠B-OSE_Labeled_AE   respiratory≠I-OSE_Labeled_AE   distress≠I-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE ,  interstitial≠B-OSE_Labeled_AE   lung≠I-OSE_Labeled_AE   disease≠I-OSE_Labeled_AE  as manifested by  respiratory≠B-NonOSE_AE   failure≠I-NonOSE_AE  (including  fatal≠B-NonOSE_AE  outcomes),  obliterative≠B-OSE_Labeled_AE   bronchiolitis≠I-OSE_Labeled_AE ,  organizing≠B-OSE_Labeled_AE   pneumonia≠I-OSE_Labeled_AE ,  alveolitis≠B-OSE_Labeled_AE   allergic≠I-OSE_Labeled_AE ,  pneumonitis≠B-OSE_Labeled_AE ,  pulmonary≠B-OSE_Labeled_AE   hemorrhage≠I-OSE_Labeled_AE ;  respiratory≠B-OSE_Labeled_AE   distress≠I-OSE_Labeled_AE ,  pulmonary≠B-OSE_Labeled_AE   hypertension≠I-OSE_Labeled_AE ,  pulmonary≠B-OSE_Labeled_AE   edema≠I-OSE_Labeled_AE ,  pleural≠B-OSE_Labeled_AE   effusion≠I-OSE_Labeled_AE ,  bronchospasm≠B-OSE_Labeled_AE ,  dyspnea≠B-OSE_Labeled_AE ,  hypoxia≠B-OSE_Labeled_AE ,  cough≠B-OSE_Labeled_AE ,  nasal≠B-OSE_Labeled_AE   congestion≠I-OSE_Labeled_AE ,  nasal≠B-OSE_Labeled_AE   discomfort≠I-OSE_Labeled_AE ,  oropharyngeal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  rhinorrhea≠B-OSE_Labeled_AE .

    Skin≠B-NonOSE_AE   and≠I-NonOSE_AE   Subcutaneous≠I-NonOSE_AE   Tissue≠I-NonOSE_AE :   toxic≠B-OSE_Labeled_AE   epidermal≠I-OSE_Labeled_AE   necrolysis≠I-OSE_Labeled_AE ,  Stevens≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  Johnson≠I-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE ,  erythema≠B-OSE_Labeled_AE   multiforme≠I-OSE_Labeled_AE ,  palmar≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  plantar≠I-OSE_Labeled_AE   erythrodysesthesia≠I-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE ,  radiation≠B-OSE_Labeled_AE   recall≠I-OSE_Labeled_AE   dermatitis≠I-OSE_Labeled_AE ,  toxic≠B-OSE_Labeled_AE   skin≠I-OSE_Labeled_AE   eruption≠I-OSE_Labeled_AE ,  urticaria≠B-OSE_Labeled_AE ,  dermatitis≠B-OSE_Labeled_AE ,  blister≠B-OSE_Labeled_AE ,  pruritus≠B-OSE_Labeled_AE ,  erythema≠B-OSE_Labeled_AE ,  nail≠B-OSE_Labeled_AE   disorder≠I-OSE_Labeled_AE ,  facial≠B-OSE_Labeled_AE   swelling≠I-OSE_Labeled_AE ,  hyperhidrosis≠B-OSE_Labeled_AE .

    Tumor≠B-NonOSE_AE   lysis≠I-NonOSE_AE   syndrome≠I-NonOSE_AE   :    like other cytotoxic drugs, cyclophosphamide may induce  tumor≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  lysis≠I-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE  and  hyperuricemia≠B-OSE_Labeled_AE  in patients with rapidly growing  tumors≠B-Not_AE_Candidate .

    Vascular≠B-NonOSE_AE :   pulmonary≠B-OSE_Labeled_AE   embolism≠I-OSE_Labeled_AE ,  venous≠B-OSE_Labeled_AE   thrombosis≠I-OSE_Labeled_AE ,  vasculitis≠B-OSE_Labeled_AE ,  peripheral≠B-OSE_Labeled_AE   ischemia≠I-OSE_Labeled_AE ,  hypertension≠B-OSE_Labeled_AE ,  hypotension≠B-OSE_Labeled_AE ,  flushing≠B-OSE_Labeled_AE ,  hot≠B-OSE_Labeled_AE   flush≠I-OSE_Labeled_AE .

